Is allergic sensitization relevant in severe asthma? Which allergens may be culprits?

Lombardi, Carlo; Savi, Eleonora; Ridolo, Erminia; Passalacqua, Giovanni; Canonica, Giorgio Walter

doi:10.1186/s40413-016-0138-8

Cited by 38 publications

(43 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well established that inner-city children present a high burden of asthma symptoms and morbidity even when complying with guidelines-directed management [7]●●[8]. Cockroach and mouse represent a significant percentage of allergic sensitization in this population, which is highly exposed to allergens from both sources [9,10]●●[11].…”

Section: Cockroach Allergy and Inner-city Asthmamentioning

confidence: 99%

New Insights into Cockroach Allergens

Pomés

Mueller

Randall

et al. 2017

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of review This review addresses the most recent developments on cockroach allergen research in relation to allergic diseases, especially asthma. Recent findings The number of allergens relevant to cockroach allergy has recently expanded considerably up to 12 groups. New X-ray crystal structures of allergens from groups 1, 2 and 5 revealed interesting features with implications for allergen standardization, sensitization, diagnosis and therapy. Summary Cockroach allergy is strongly associated with asthma particularly among children and young adults living in inner-city environments, posing challenges for disease control. Environmental interventions targeted at reducing cockroach allergen exposure have provided conflicting results. Immunotherapy may be a way to modify the natural history of cockroach allergy and decrease symptoms and asthma severity among sensitized and exposed individuals. The new information on cockroach allergens is important for the assessment of allergen markers of exposure and disease, and for the design of immunotherapy trials.

show abstract

Section: Cockroach Allergy and Inner-city Asthmamentioning

confidence: 99%

New Insights into Cockroach Allergens

Pomés

Mueller

Randall

et al. 2017

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…An allergic component, as evidenced by IgE antibodies to a relevant airborne allergen, manifests in $80% of patients with asthma, and is often responsible for severe or treatment-refractory disease 4,5 . Omalizumab (Xolair; Novartis Pharmaceuticals Corporation; East Hanover, NJ Genentech USA, Inc.; South San Francisco, CA), an anti-IgE monoclonal antibody, represented the first therapeutic agent that specifically addressed the role of allergy in moderate-to-severe asthma.…”

Section: Introductionmentioning

confidence: 99%

Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

Corren

Kavati

Ortiz

et al. 2017

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: Randomized controlled trials (RCTs) have established the safety and efficacy of omalizumab on clinical parameters, and have also evaluated its impact on patient-reported outcomes (PROs). The purpose of this systematic literature review was to review published data based on PRO endpoints in order to determine the benefit of omalizumab as add-on therapy to inhaled corticosteroids in patients with moderate-to-severe persistent allergic asthma. Methods: A systematic literature review was conducted of reference databases and recent conferences. RCTs of add-on omalizumab therapy in adults, adolescents, and children with moderate-to-severe persistent asthma were included. Two researchers independently screened and reviewed articles with regards to inclusion and exclusion criteria for relevant studies. Results: Twenty-six trials met the criteria for inclusion. Of these, PRO measures were included in 19 trials to capture the impact of omalizumab on symptoms, 11 assessed patients for health-related quality-of-life (HRQoL), and four evaluated asthma control. Other PROs related to global evaluation of treatment effectiveness and work productivity. Overall, results demonstrated a significant difference across most PROs in favor of omalizumab add-on therapy vs placebo or comparators. Conclusions: PROs are an integral part of outcome assessment in clinical trials related to asthma. The RCTs reviewed demonstrate that omalizumab treatment improves PROs in patients with moderate-tosevere persistent allergic asthma, particularly symptom control and HRQoL.ARTICLE HISTORY

show abstract

“…[17] Suggestions for asthma control strategies at the community level include a reduction in exposure to cockroach allergen. [18] Our study reiterates that such an approach could be effective in our country given the high level of sensitisation across regions.…”

Section: Discussionmentioning

confidence: 98%